AXSM News and Press, Axsome Therapeutics Inc. From 11/28/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Stock-Asso / Shutterstock.com Swvl (NASDAQ: SWVL ) layoffs are here again as the micro-mobility company seeks to reduce costs by cutting more than 50% of its workforce. According to Swvl, these lates...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: pathdoc / Shutterstock.com Axsome Therapeutics (NASDAQ: AXSM ) stock is soaring higher on Monday after releasing positive results from a Phase 3 clinical trial. That Phase 3 clinical trial covers Alzh...

AXS-05 statistically significantly delayed time to relapse of Alzheimer’s disease agitation versus placebo (p=0.014, primary endpoint) AXS-05 statistically significantly prevented relapse of Alzheimer’s disease agitation versus placebo (p=0.018, key secondary endpo...

Most stocks don't deliver explosive gains. That's obvious by simply looking at the performance of indexes that track the total stock market. There are a few that do, though. They're the kinds of stocks that many investors kick themselves for not buying earlier. It's hard to spot these p...

Biotech company Axsome Therapeutics (NASDAQ: AXSM) has had a strong -- although somewhat volatile -- year on the stock market. The company's shares have been up about 50% since early January. Axsome has key regulatory developments to thank for that performance. What's more, the ...

NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executiv...

Here's a fact: You don't need huge sums of money to start (or continue) investing. Any amount, if placed wisely, could eventually bring you great returns. Today, let's consider $500. With that amount you could buy one of the following growth stocks -- or invest in all three. They could doub...

Summary Currently, several pharmaceutical companies are testing candidates’ drugs and some of them are in the final stages of trials. The huge revenue potential is at stake in this race for the best anti-agitation drug for dementia and Alzheimer's patients. BioXcel's BX...

Axsome Therapeutics (NASDAQ: AXSM) has had a transformative past 10 months. The biotech company started the year with no drugs on the market, and now its portfolio includes two therapies. That's partly why Axsome stock has crushed the market this year -- although it has been a bit o...

NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executiv...